PC
KZR

Polar Capital’s Kezar Life Sciences KZR Stock Holding History

Polar Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-15,000
Closed -$1.16M – 294
2019
Q2 		$1.16M Buy
15,000
+5,000
+50% +$778K 0.01% 260
2019
Q1 		$1.77M Buy
+10,000
New +$1.97M 0.02% 242

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Polar Capital's KZR Position: Q3 2019 in Review

Polar Capital sold out of Kezar Life Sciences (KZR) in Q3 2019, closing a stake of 15,000 shares — an estimated $1.16M sold.

Polar Capital first reported a position in KZR in Q1 2019 and held it in 2 quarters. The position peaked at $1.77M in Q1 2019. 54 funds tracked by Wall St. Rank hold KZR as of Q3 2019.

  • Polar Capital reported no remaining Kezar Life Sciences position as of Q3 2019 after selling out during the quarter.
  • Polar Capital sold 15,000 Kezar Life Sciences shares in Q3 2019, an estimated $1.16M.
  • Polar Capital first reported a position in Kezar Life Sciences in Q1 2019 and held it in 2 quarters.
  • Polar Capital's Kezar Life Sciences position peaked at $1.77M in Q1 2019.
  • 54 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2019.

Based on Polar Capital's 13F filing for Q3 2019, filed 14 Nov 2019.